Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Cambridge Cognition Holdings ( (GB:COG) ).
Cambridge Cognition has announced its involvement in the Intuition Brain Health study, one of the largest brain health studies ever conducted, which demonstrates the value of its CANTAB digital cognitive assessments. The study, published in Nature Medicine and sponsored by Biogen in collaboration with Apple, enrolled 23,004 participants and highlighted the scalability and sensitivity of Cambridge Cognition’s platform for remote cognitive evaluation. This positions the company as a leader in digital brain health solutions, with significant market opportunities for real-world brain health monitoring applications.
More about Cambridge Cognition Holdings
Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers four core products: CANTAB assessments, a flexible eCOA platform, rater training services, and quality assurance tools. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.
YTD Price Performance: 13.33%
Average Trading Volume: 60,776
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £17.79M
See more insights into COG stock on TipRanks’ Stock Analysis page.